What they were paid
Karyopharm Therapeutics Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $70,000 | $0 | $15,142 | $0 | $85,142 |
| FY2024 | $70,000 | $0 | $46,078 | — | $116,078 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Karyopharm Therapeutics Inc. DEF 14A filed April 13, 2026, accession 0001503802-26-000023, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Karyopharm Therapeutics pays directors a $50,000 cash retainer.
The rest of the Karyopharm Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Barry E. Greene | Lead Independent Director | $130,142 |
| Christy J. Oliger | Independent Director | $95,142 |
| Deepika R. Pakianathan, Ph.D | Independent Director | $105,142 |
| Garen G. Bohlin | Independent Director | $95,142 |
| Mansoor Raza Mirza, M.D | Independent Director | $116,555 |
| Richard Paulson, M.B.A | Director | $0 |
| Zhen Su, M.D., M.B.A | Independent Director | $75,142 |
The full Karyopharm Therapeutics compensation record
free company briefThis page is one director within Karyopharm Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat